Meprobamate in Chronic Psychiatric Patients

Hollister, Leo E.; Elkins, H. K.; Hiler, Emerson G.; Pierre, Roderick St.

doi:10.1111/j.1749-6632.1957.tb46016.x

Cited by 18 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Much earlier, meprobamate was reported to be helpful in some depressed patients. 46 A controlled comparison of meprobamate, protriptyline, a combination of the two drugs, and placebo indicated that patients improved significantly more after receiving the three drugs than after the placebo. 97 A combination of meprobamate and benactyzine has been quite popular in clinical practice, despite a poor rationale for such a mixture and few adequate clinical studies.…”

Section: Clinical Pharmacologymentioning

confidence: 99%

Clinical use of psychotherapeutic drugs: Current status

Hollister

1969

Clin Pharma and Therapeutics

Self Cite

View full text Add to dashboard Cite

The clinical efficacy of present psychotherapeutic drugs varies among the various types. Antianxiety agents are most controversial, as a great many confounding, metapharmacological variables influence the results obtained. The use of such drugs in traditional doses and dosage schedules also may not employ them to best advantage. Antidepressants must increasingly be considered in relation to the clinical type of depressive reaction being treated. Tricyclic drugs are clearly indicated for retarded or endogenous depressions; in exceptional cases, monoamine oxidase inhibitors may merit a trial in such patients. Depressions characterized by much attendant anxiety may respond better to phenothiazines or to antianxiety agents. Consequently, the scope of “antidepressants” may be larger than simply one or two drug classes. Antipsychotics are clearly effective. A large number of peer drugs are available, although it seems clear that, for reasons still to be elucidated, individual patients may respond better to one than to another. Drug therapy of other types of psychiatric disorder, such as mental retardation, childhood and adolescent behavior disorders, alcoholism, and psychoses associated with old age, is of limited value. Lithium salts may represent a significant advance in the management and prevention of manic attacks.

show abstract

Section: Clinical Pharmacologymentioning

confidence: 99%

Clinical use of psychotherapeutic drugs: Current status

Hollister

1969

Clin Pharma and Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The efficacy of meprobamate and promazine used separately in the treatment of psychiatric disorders has been well established by numerous investigators (6–13). Settel (14), however, was the first to use a combination of these agents, in predetermined amounts, in the treatment of senile patients.…”

Section: Meprobamate and Promazine Hydrochloridementioning

confidence: 99%

Meprobamate‐promazin E Therapy for Aged Psychiatric Patients With Chronic Brain Syndrome Associated With Arteriosclerosis

Kozlowski¹

1961

J American Geriatrics Society

View full text Add to dashboard Cite

“…In man, double-blind clinical trials on meprobamate (Hollister et al, 1957) have shown improvement of anxiety neuroses and even of certain psychoses. In contrast to the effects of the other tranquillizers, it did not impair performance or level of aspiration in psychological experiments on the triple tester (Steinberg, 1957).…”

Section: Meprobamatementioning

confidence: 99%

Pharmacology of Tranquillizing Drugs

Vogt¹

1958

BMJ

View full text Add to dashboard Cite

Meprobamate in Chronic Psychiatric Patients

Cited by 18 publications

References 6 publications

Clinical use of psychotherapeutic drugs: Current status

Clinical use of psychotherapeutic drugs: Current status

Meprobamate‐promazin E Therapy for Aged Psychiatric Patients With Chronic Brain Syndrome Associated With Arteriosclerosis

Pharmacology of Tranquillizing Drugs

Contact Info

Product

Resources

About